industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Health/Medical Newsfeed


Tuesday, September 27th, 2011

New White Paper for Dietary Supplement Manufacturers Provides How-to for New FDA Compliance Paradigm

Critical information that dietary supplement manufacturers must know in order to meet the Federal Food & Drug Administration’s (FDA) good manufacturing practices “compliance paradigm” is detailed in a free white paper available at http://www.microtestlabs.com/dietarypaper.

The white paper, “Dietary Supplements — A New Paradigm for Manufacturers,” provides how-to guidance for manufacturers of dietary supplements – a fast-growing market, which totaled $23 billion and more than 40,000 products in 2008.

Just 15 years ago, the production of dietary supplements was regulated as food ingredients without oversight. Today, the FDA regulates their manufacture under the current Good Manufacturing Practices (cGMP) for Dietary Supplements, listed in 21 Code of Federal Regulations (CFR) 111.

“Today, there’s a new paradigm for dietary supplement manufacturers – and it’s one of testing, manufacturing, and lot release. cGMP controls are used to assure that products meet the requirements of safety and have the strength and identity to meet the label claims.  And label claims are the driver for all FDA regulatory actions,” said Steven G. Richter, Ph.D., RAC, SM (NRM), author of the white paper, and President and Chief Scientific Officer of Microtest Laboratories.

“In fact, this new ‘compliance paradigm’ dietary supplement manufacturers is very similar to pharmaceutical manufacturing. The problem is that, for many small- and medium-sized companies which produce dietary supplements, compliance with the spirit and intent of the cGMPs is proving to be a challenge,” he said.

For those manufacturers, the white paper provides a much needed overview and discussion of what’s required of the by the FDA, including how-to guidance on:

  • Developing the Necessary Quality System
  • Management “Buy In”
  • Microbiological Testing/Practices In The USP Dietary Supplement Compendium and FDA BAM
  • Chemistry and Manufacturing Controls (CMC)

The white paper is available at: http://www.microtestlabs.com/dietarypaper.

“The challenges for small and medium sized manufacturers are these: Testing dietary supplements and determining compliance requires the personnel and facilities to handle large-scale testing programs. The ability to train and retain these employees may be a challenge. And a full cGMP assessment is required for each manufacturer.

“Compliance with the intent of the law will be determined by management’s buy-in to a robust quality program with concomitant lab support,” Richter said. “Given all this, for many small and medium sized manufacturers, outsourcing the majority of their testing may make most economical sense.”

For a full discussion of the issues surrounding the FDA’s Good Manufacturing Practices (cGMP) for Dietary Supplements, download the new, free white paper, “Dietary Supplements — A New Paradigm for Manufacturers,” from http://www.microtestlabs.com/dietarypaper.

For more information, visit http://www.microtestlabs.com. Follow Microtest Labs on Twitter@MicrotestLabs at http://twitter.com/MicrotestLabs.

About Microtest

Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visithttp://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.


Wednesday, September 21st, 2011

Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories

AGAWAM, Mass. — Building, validating, and maintaining a controlled environment facility is the subject of a daylong seminar on Oct. 18, 2011, hosted by Microtest Laboratories at the MIT Endicott House in Dedham, Massachusetts.

Titled “Keeping It Clean? The Building Blocks of Facility Control,” the seminar will focus on the clean room testing, disinfection validation, and related contamination testing issues that arise from manufacturing of medical devices or pharmaceuticals, as well as sterile compounding in hospital pharmacies.

In each seminar program, industry experts will present practice advice and sound solutions in an interactive format that will encourage a high level of engagement by participants for questions, answers and discussion. The topics will include:

  • Killing The Bugs Without Killing Yourself: Disinfectant Qualifications
  • Feeling Like A Fish Out of WFI?: Water System Validation and Maintenance
  • Got A Lot On Your Plate: Clean-room Validations and Maintenance
  • The Old In & Out: Considerations On Insourcing vs. Outsourcing

Keeping It Clean? The Building Blocks of Facility Control” will be presented 8:30 a.m. to 3:30 p.m. on Tuesday, Oct. 18, 2011, at the MIT Endicott House, 80 Haven Street in Dedham, Mass., just outside of Boston. Registration and a complimentary continental breakfast is at 8 a.m. Lunch will be served at Noon. The cost is $149 per person and includes meals, refreshments, and workshop handouts.

To register or for more information, visit the Microtest Laboratories website at http://www.microtestlabs.com/seminar/index.asp. Or, contact Julie Adamski at 413-786-1680, toll-free at 1-800-631-1680, or at jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in controlled environment facility testing, laboratory testing, and contract manufacturing services for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Press contact: Don Goncalves, Tiziani Whitmyre, 1-781-793-9380, dgoncalves@tizinc.com

 


Wednesday, September 14th, 2011

Robert F. Higgins Joins Advanced Practice Strategies Board of Directors

— Healthcare Investor Joins Leading Continuing Medical Education Provider —

Boston, Mass., September 14, 2011 — Advanced Practice Strategies (APS), the leading provider of continuing medical education solutions for risk management and patient safety, today announced that Robert F. Higgins, founding partner of Highland Capital Partners and Senior Lecturer at Harvard Business School, has been elected to APS’ Board of Directors.

“Bob has a remarkable track record working with early-stage healthcare companies,” said Dennis Ferrill, chief executive officer of APS. “His expertise in the healthcare industry will enable him to make significant contributions to the APS board. I look forward to working with him as APS undergoes a period of rapid growth and expansion as we advance outdated continuing medical education practices and dramatically improve patient safety.”

“APS represents an outstanding opportunity to expand the knowledge base of our nation’s medical professionals,” said Higgins. “Medical error is a massive and growing problem. APS is building the next generation of learning tools for physicians, nurses, and other medical professionals. I look forward to working with Dennis and the team to improve the performance of clinical professionals and enhance patient outcomes.”

At Highland Capital Partners, Higgins has helped build many successful companies in the healthcare service, IT, medical device, and biotechnology sectors. He has served as a director for numerous public and private firms. Higgins is a former director of the National Venture Capital Association and president of the New England Venture Capital Association. In addition, he has been recognized by the prestigious Forbes Midas List and AlwaysOn Venture Capital 100 as one of the top venture capitalists in the industry.

At Harvard Business School, Higgins co-created and currently teaches a course titled, “Entrepreneurship and Venture Capital in Healthcare.” He is a member of the Healthcare Initiative, the Social Enterprise Initiative, and the Harvard Faculty Committee for the MD/MBA program. In addition, he received the 2008 HBS Healthcare Alumni Achievement Award.

Prior to founding Highland, Higgins was the chief executive of the John A. Hartford Foundation, the Clark Foundation, and the Burden Foundation. He was also the assistant to the U.S. Secretary of Commerce and assistant to the head of the international division of the U.S. Treasury. He is a graduate of Harvard College and Harvard Business School.

About APS

Advanced Practice Strategies (APS) is building the next generation of continuing medical education for physicians, nurses, and other medical professionals. APS is dedicated to improving the lives of both patients and their caregivers through effective, innovative education solutions. APS’ flexible, state-of-the-art eLearning program has helped hospitals and clinicians reduce risk and enhance patient safety across the country. APS’ Demonstrative Evidence Group is the nation’s leading provider of visual strategies and materials for courtroom defense against medical malpractice claims. Strategic partners include the Risk Management Foundation of the Harvard Medical Institutions and the Hospital Corporation of America. APS is headquartered in Boston, Massachusetts. For more information, visit http://www.aps-web.com.

# # #

Media Contact: Don Goncalves, dgoncalves@tizinc.com, 781-793-9380


Monday, July 25th, 2011

Advanced Instruments Introduces A2O Advanced Automated Osmometer Featuring Breakthrough Automation and Performance Levels

a2o-150NORWOOD, MASSACHUSETTS, USA, July 25, 2011 - Advanced Instruments, Inc., today introduced the A2OTM Advanced Automated Osmometer, a multi-sample instrument that sets new benchmarks for analytical performance, ease of use, and true walk away operation capabilities in osmolality testing. The announcement was made at the American Association for Clinical Chemistry’s 2011 Clinical Lab Expo.

“The A2O represents a major step forward in osmometry technology and offers clinical laboratory customers an exceptional opportunity to enhance their productivity and workflow,” said Kelly Peterson, product manager, Advanced Instruments. “It combines a highly functional design, exceptional performance, and an intuitive software control package that is both powerful and elegantly simple to operate.”

A2O Eliminates Time-Consuming Manual Pipetting

With its intelligent liquid handling, the A2O is the first osmometer to eliminate time-consuming and labor-intensive manual pipetting – the leading cause of sampling errors and inaccurate test results. The instrument fully automates sample processing to achieve dramatic gains in laboratory productivity and efficiency.

The instrument’s flexible software brings exciting new features and benefits to clinical laboratories:

  • Intuitive touchscreen interface provides easy-to-use functionality and operation
  • Integrated quality control features include automated system calibration, statistical monitoring and reporting, method control limits for controls and patient samples, and built-in system linearity checks
  • Selectable system operation and access levels provides operator login and password protection
  • Positive sample identification eliminates transcription errors
  • Sample testing protocols can be customized specifically for each laboratory’s unique test requirements

“Advanced Instruments has leveraged its 50 years of freezing-point technology experience to revolutionize osmolality testing,” said Peterson. “The A2O’s technology will allow clinical laboratory users to achieve more results, faster – and more efficiently.”

For more information on the A2O Advanced Automated Osmometer, visit http://www.aicompanies.com/A2O or call +1 781.320.9000.

About Advanced Instruments, Inc.

Advanced Instruments, Inc., and our subsidiaries, Delta Instruments and Mart® Microbiology, design and manufacture instrumentation for clinical, pharmaceutical, biotechnology, microbiology, and food laboratories. Our quality brands include Spiral Biotech, Fiske Associates, and D & F Control Systems. The products we make help healthcare providers improve their quality of care, and industrial companies enhance their quality and productivity.

Advanced Instruments products are available from a worldwide distributor network. For more information on our products and services or to find your nearest distributor, visit us at http://www.aicompanies.com or e-mail us at info@aicompanies.com.

# # #

Note to Editors:


Wednesday, July 6th, 2011

Microtest Laboratories Announces New Fast-Track Toxicity Testing for Medical Devices Using Zebrafish Embryos

AGAWAM, MASS. - July 6, 2011 - Microtest Laboratories has announced a new fast-track test to screen plastics and polymers in medical devices for toxicity using Zebrafish embryos (Danio rerio), a technique already widely utilized in drug development studies.

zebrafish“Testing has revealed that Zebrafish embryos are highly susceptible to toxins. In fact, Zebrafish labs are ubiquitous in most universities and research hospitals,” said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories, and former U.S. Food & Drug Administration (FDA) official.

“We’ve confirmed the application of Zebrafish embryos in the toxicity testing of materials used in medical devices,” Dr. Richter said. “With our in-vitro test, manufacturers and bio materials researchers can screen thousands of polymers in less than a week – yielding significant economic savings in both the time and expense of medical device testing.”

In its research, Microtest Laboratories found that the current “gold standard” USP Cytotoxicity Assay, which utilizes live mouse fibroblasts (L929) cells in culture, failed to detect the toxicity of a BPA extract during testing – while Microtest’s new Zebrafish embryo screen succeeded.

BPA (bis-phenol A) is a suspected toxic polymer assumed as having both carcinogenic and teratogenic effects on humans. The U.S. Environmental Protection Agency (EPA) has indicated that BPA will be slated for screening soon.

“Microtest’s new Zebrafish embryo assay has better sensitivity and generates more scientific data than the small animal tests currently recommended by the FDA,” Dr. Richter said.

“The use of Zebrafish embryos will reduce or eliminate the current animal testing required for all medical devices testing. This important vertebrate model has demonstrated similarities to mammalian models and humans in toxicity testing,” he noted.

Microtest Laboratories’ new Zebrafish embryo assay for the toxicity testing of medical devices is immediately available. For more information, visit http://www.microtestlabs.com/zebrafish-embryos-testing or call 1-413-786-1680 or toll-free 1-800-631-1680

About Microtest Laboratories

Microtest Laboratories is a leader in medical device testing and related services for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Press Contact: Don Goncalves, Tiziani Whitmyre, 781-793-9380, dgoncalves@tizinc.com

Download high resolution image from: http://www.microtestlabs.com/photos


Tuesday, June 7th, 2011

New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes

A free white paper that guides manufacturers of medical devices in the validation of their cleaning processes is available from Microtest Laboratories.

It is available for download from: http://microtestlabs.com/cleaning-validation-paper

As many medical devices are made of high-tech materials such as metallic alloys or synthetic plastics, manufacturers may require the use of various agents to aid in the manufacturing process, or produce contaminants that need to be removed. Thus, these products must be cleaned to ensure both patient safety and the continuing functionality of the device.

In the white paper titled, “Five Steps to Validating the Cleaning Process of Medical Devices,” Patrick Kenny, Manager of Analytical Services at Microtest Laboratories, reviews medical device regulation under 21 CFR Part 820 – Quality System Regulation.

Several sections of Part 820 can be directly related to medical device cleanliness. For manufacturers, the challenge is to validate the cleaning process to ensure the devices are free of residue (chemical and particulate) in order to ensure patients are safe.

In the paper, Kenny presents a five-step process that provides a framework to assist manufacturers of medical devices in their cleaning validation efforts:
#1: Evaluate the Process, Determine the Potential Contaminants
#2: Determine the Limits
#3: Identify the Analytical Test
#4: Validate the Method for Use
#5: Validate the Cleaning Process

Download a free copy of “Five Steps to Validating the Cleaning Process of Medical Devices,” at http://microtestlabs.com/cleaning-validation-paper.

At Microtest Labs, Kenny leads the services group performing medical device and pharmaceutical analytical testing. He holds a M.S. degree in Chemistry and has spent the past 13 years working in QC, R&D and manufacturing laboratories.

About Microtest Laboratories
Microtest Labs is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Labs on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs


Tuesday, May 31st, 2011

Immunetics Receives $500,000 from Massachusetts Life Sciences Center to Commercialize BacTx® Test for Bacterial Contamination in Platelet Transfusions

Immunetics, Inc., today announced it has been awarded a $500,000 Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) to commercialize its BacTx® rapid test for detecting bacterial contamination in platelets.

Platelets are a vital blood product enabling clotting, and patients suffering from trauma, surgical procedures, cancer, or chemotherapy must receive platelet transfusions to survive. Bacterial contamination of platelets is the leading cause of infection during transfusion, with patients facing the risk of severe or fatal transfusion-associated sepsis from the roughly 1 in 2,000 platelet units that are contaminated.

“Rapidly detecting bacteria in platelet units presents a major challenge. Some current testing methods are ineffective because of low sensitivity. Others are overly difficult or time-consuming to perform close to transfusion,” said Dr. Andrew Levin, president and scientific director, Immunetics.

“According to the American Association of Blood Banks (AABB), a rapid test with high sensitivity performed close to the time of transfusion would represent a breakthrough in transfusion safety. The Massachusetts Life Sciences Center grant will help us transition the critical juncture from R&D to manufacturing scale-up and regulatory approval — and commercially launch BacTx,” Levin said.

Immunetics has concluded clinical trials for BacTx® and plans to submit an application for approval to the U.S. Food and Drug Administration (FDA) this summer. With FDA approval, BacTx® could be launched as early as this year.

Immunetics was one of four life sciences firms named by the Massachusetts Life Sciences Center’s Board of Directors (“the Center”) to share in $2 million in new SBMGs. The four recipients were chosen through a competitive process after extensive review by the Center’s peer review panel, Scientific Advisory Board, and Board of Directors. The grants foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster.

“Helping our life sciences companies grow is all about creating jobs,” said Governor Deval Patrick. “As we continue to strengthen our global leadership in the life sciences, the Center’s Small Business Matching Grant Program is meeting an important need and making Massachusetts an even more attractive place for life sciences companies to locate and grow.”

“The SBMG program is another example of the Center’s leveraging strategy,” said Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center. “Federal SBIR/STTR grants provide Massachusetts companies with funds for their research and development; our SBMG program then provides the funds that companies need to bridge to commercialization. These four promising companies will bring cost-effective new treatments to the market and expand employment opportunities in Massachusetts. We are especially pleased that some of our grantees will contribute directly to the creation of biomanufacturing jobs in the Commonwealth.”

“As an author of the legislation creating the Life Sciences Center several years ago, I am excited about the wonderful opportunity to grow the Life Sciences industry on the South Boston Waterfront,” said State Senator Jack Hart (D-South Boston).

“Immunetics is doing important work to prevent infectious disease and improve public health in our state and around the world,” said State Representative Nick Collins (D-South Boston), a member of the Joint Committee on Economic Development and Emerging Technologies. “This award by the Massachusetts Life Sciences Center is an example of the Commonwealth’s commitment to investing in our state’s economic future. It is also another sign of the continued emergence of the South Boston Waterfront as a center for innovation and job creation in the life sciences industry.”

“I am extremely grateful for the continuing support by the Commonwealth and the Massachusetts Life Sciences Center of our mission to introduce innovations in the diagnosis of infectious diseases, as we grow our company in South Boston and become a stronger part of — and employer in — the very exciting Massachusetts Life Sciences community,” Levin said.

Immunetics received two SBIR Phase II grants totaling approximately $4 million from the National Heart, Lung, and Blood Institute (NHLBI), an agency of the National Institutes of Health (NIH), which supported the research and development of the test. The technology underlying the test is protected by a recently issued U.S. patent, and foreign patents with approved claims are in process of issue.

With FDA approval, the BacTx® test will be marketed to blood centers and hospitals throughout the U.S. and around the world. In total, about 5 million platelet units are collected annually in the U.S. and an equal number outside the U.S.

About Immunetics, Inc.

Immunetics Inc. (http://www.immunetics.com), offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over 10 years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is to deliver better, cost-efficient care through more accurate diagnosis. Immunetics is headquartered in Boston, Mass. Follow Immunetics on Twitter at http://twitter.com/immunetics.

# # #

Press Contact: Don Goncalves, Tiziani Whitmyre, 781-793-9380, dgoncalves@tizinc.com


Tuesday, April 26th, 2011

ASCO Numatics to Merge Miniature Valve Products Under the ASCO Brand

FLORHAM PARK, NEW JERSEY, USA April 26, 2011ASCO Numatics, the world’s leading manufacturer of comprehensive fluid automation, flow control, and pneumatics solutions, announced today it will merge all of its ASCO and Numatics miniature valve product lines under the ASCO brand, effective immediately. The products include 25 series of direct-acting miniature solenoid valves and manifolds.

“In this merger, we are taking the best products from the former ASCO Scientific and Numatics Miniature Pneumatic Group product lines to create a broader, more customer-focused family of ASCO Miniature Valve Products,” said Robert W. Kemple, Jr., executive vice president, sales and marketing — Americas, ASCO Numatics. “Our capability to rapidly customize these miniature valve solutions means product asco-miniature-valve-productsengineers will not have to change their designs to incorporate our products.”

ASCO miniature valve products are ideal for engineers developing medical equipment and analytical instrumentation. The solutions can be customized to easily interface with existing product designs. Valve specifications can be adjusted to achieve the desired performance, and specific wire terminations can be selected for easy plug-and-play connectivity.

“ASCO’s heritage of product quality and reliability will be highly attractive for critical medical system applications such as oxygen concentrators, critical-care ventilators, dialysis machines, and blood analyzers,” said Kemple. “All of our miniature valve products will be built in a clean room environment to eliminate airborne contamination, and complete assemblies will be tested to each customer’s requirements.”

ASCO miniature valve products are supported by the largest engineering and technical support team in North America. “Our technical and field sales personnel will help customers identify specific miniature valve solutions that will reduce cost and extend equipment life,” Kemple said.

To receive the new ASCO Miniature Valve Products catalog or get more information, call ASCO at 800-972-ASCO, e-mail info-valve@asco.com, or visit www.ascovalve.com/miniature.

About ASCO Numatics

ASCO Numatics, a division of Emerson, offers comprehensive fluid automation solutions, including flow control and pneumatics products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit www.asconumatics.com

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets through its network power, process management, industrial automation, climate technologies, and tools and storage businesses. Sales in fiscal 2010 were $21 billion. For more information, visit www.Emerson.com.

# # #

Notes to Editors:

Press Contact: Don Goncalves, Tiziani Whitmyre, Inc., 781-793-9380, dgoncalves@tizinc.com

Download high resolution image for publication: http://bit.ly/ASCOMiniature


Wednesday, April 6th, 2011

Seminar to Help Manufacturers Accelerate the Process of Bringing Reusable Medical Devices to Market

AGAWAM, Mass. – Medical product manufacturers can learn how to accelerate the process of bringing their reusable devices to market in a day-long seminar on May 3, 2011, in Dedham, Massachusetts.

Titled “Bringing Your Reusable Device To Market: Just Because Your Device Lasts Forever Doesn’t Mean The Process of Bringing It To Market Has To,” the seminar will provide an extensive look at the process of introducing such products and help manufacturers answer critical questions such as: “What is required?”; “How much will it cost?”; and “How long will it take?”

The seminar will cover the product introduction process from manufacture of the sterilization tray to the testing that’s required for regulator submittal. Presentations will include:

  • Flushing It Out: New Analytical Methods of Testing on Protein, Hemoglobin, and Carbohydrate
  • Don’t Get Stuck in a Groove: Cleaning Validations Using Microbial Methods
  • What is the Good in Good Laboratory Practices (GLP): Understanding the Process
  • Packaging Your Idea Into Reality: A Look at the Process of Tray Manufacturing
  • One Cycle, Two Cycle, Three Cycle, More?: Sterilization of Your Reusable Devices

The event will run from 8:30 a.m. to 3:30 p.m., with registration and a complimentary continental breakfast starting at 8 a.m. The seminar will be held on Tuesday, May 3, 2011, at the MIT Endicott House, 80 Haven Street, Dedham, Massachusetts. The cost is $149 per person and it includes breakfast, lunch, and workshop handouts.

The seminar is sponsored by Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries.

To register, contact Julie Adamski at 413-786-1680, toll-free at 800-631-1680, or at jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Press contact: Don Goncalves, 1-781-793-9380, dgoncalves@tizinc.com


Tuesday, March 29th, 2011

New Sync Stereo Earmuffs from Howard Leight Combine Hearing Protection with High-Fidelity Sound Quality

syncipodSMITHFIELD, R.I.March 29, 2011 – Optimizing acoustical earcup design, volume management technology, and personal hearing protection, Honeywell Safety Products introduces SyncTM, the next generation of stereo earmuffs from Howard Leight®. Sync delivers the proper levels of hearing protection in hazardous noise environments with high-fidelity stereo sound from users’ personal portable audio MP3 players.

“Most stereo earmuffs used in industry today provide a moderate level of hearing protection, but often sacrifice the sound quality of the attached MP3 players – which can work to discourage their use,” said Renee S. Bessette, COHC, Global Brand Manager, Howard Leight / Honeywell Safety Products. “In contrast, Sync stereo earmuffs optimize new designs and technologies that provide both hearing protection and true listening enjoyment. Sync entices usage – to deliver protection from noise-induced hearing loss (NIHL) on the job or at home.”

Sync stereo earmuffs feature:

  • Protection from Hazardous Noise - With an NRR 25, Sync provides ideal, consistent hearing protection and ensures appropriate attenuation in most industrial environments. Sync’s Volume Management TechnologyTM manages sound levels reaching the user’s ear to a safe level.
  • Plug In and Go - There are no volume knobs or power switches to coordinate nor batteries to replace. Ease-of-use is enhanced by maintaining volume and power control through the MP3 device. Users simply plug MP3 players and personal audio devices and listen.
  • Personal Listening – Sync can be used with a user’s own MP3 player, mobile phone and other personal audio devices, ideal for use at work or at home. Its technologically advanced acoustical bass chamber enhances bass sounds that are typically sacrificed in industrial stereo earmuffs.
  • Cool, Modern Style – Sync’s earcup design is DJ-inspired, and the sound quality is on par with other professional audio headphones. Sync’s stylish design easily surpasses other industrial earmuffs. Both comfort and fit are ensured by its padded diamond-patterned headband and its reinforced forkslides that keep it in place when worn.

Sync is now available for ordering through industrial safety distributors in the U.S. and Canada.

For more information, visit http://www.howardleight.com/playitsafe.

About Howard Leight®

Howard Leight/Honeywell Safety Products is a leading global provider of passive and intelligent hearing protection solutions, and the founder of the HearForeverTM initiative.  For over 30 years, Howard Leight has pursued the prevention of occupational noise-induced hearing loss through innovation in hearing protection design, technology, performance and comfort, and the promotion of progressive Hearing Conservation Programs.  Leading solutions include the highest attenuating Max® single-use earplug; patented Air Flow ControlTM technology for optimal earmuff attenuation; QuietDoseTM personal in-ear dosimetry; and the industry-changing VeriPRO® earplug fit testing system. Visit: www.howardleight.com.

Visit the Howard Leight website at www.howardleight.com. Follow us on Twitter (@HowardLeight) at twitter.com/HowardLeight.

About Honeywell

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London, and Chicago Stock Exchanges.  For more news and information on Honeywell, please visit www.honeywellnow.com.

This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address activities, events or developments that we or our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this release are also subject to a number of material risks and uncertainties, including but not limited to economic, competitive, governmental, and technological factors affecting our operations, markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by such forward-looking statements.

# # #

Note to Editors:


Industry PR is proudly powered by WordPress.
WordPress